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Abstract 
The emergence of COVID-19 has severely compromised the arsenal of antiviral and 
antibiotic drugs. Drug discovery is a multistep process with a high failure rate, high 
cost and it takes approximately 10-12 years for the development of new molecules 
into the clinical candidate. On the other side, drug repurposing also called old drugs 
for new uses, is an attractive alternative approach for a new application of marketed 
FDA approved or investigational drugs. In the current pandemic situation raised due 
to COVID-19, repurposing of existing FDA approved drugs are emerging as the first 
line of the treatment. The causative viral agent of this highly contagious disease and 
acute respiratory syndrome coronavirus (SARS-CoV) shares high nucleotide 
similarity.  Therefore, many existing viral targets are structurally expected to be similar 
to SARS-CoV and likely to be inhibited by the same compounds. Here, we selected 
three viral key proteins based on their vital role in viral life cycle:  ACE2 (helps in entry 
into the human host), viral nonstructural proteins RNA-dependent RNA polymerase 
(RdRp) NSP12, and NSP16 which helps in replication, and viral latency (invasion from 
immunity). The FDA approved drugs chloroquine (CQ), hydroxychloroquine (HCQ), 
remdesivir (RDV) and arbidol (ABD) are emerging as promising agents to combat 
COVID-19. Our hypothesis behind the docking studies is to determine the binding 
affinities of these drugs and identify the key amino acid residues playing a key role in 
their mechanism of action. The docking studies were carried out through Autodock 
and online COVID-19 docking server. Further studies on a broad range of FDA 
approved drugs including few more protein targets, molecular dynamics studies, in-
vitro and in-vivo biological evaluation are required to identify the combination therapy 
targeting various stages of the viral life cycle.    
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Introduction 
The recent outbreak of the coronavirus disease 2019 (COVID-19) caused by the new 
coronavirus 2019-nCoV. Although the original epicenter of the COVID-19 outbreak in 
December 2019 was located in the seafood market of Wuhan city, Hubei province of 
China. [1] The disease has spread to more than 190 countries with over 1,353,361 
confirmed cases and over 79,235 confirmed deaths worldwide in a very short span of 
approximately three months as of April 08, 2020. [2] The extremely rapid chain 
transmission and deadly pathogenic nature of this virus are some of the major 
concerns for all sector of society across the world.[3] So far, the best possible solution 
of this nightmare viral disease is only social distancing which is resulting in the 
mandatory isolations/quarantines and lockdown across the word at different time 
points. [4] Further, the lives of the millions of the people and the world economy have 
been severely impacted due to this outbreak. The pathogenic nature of this agent 
implicates a plausible sever biothreat across the globe. The severity of the COVID-19 
outbreak could force to impose major changes to health system across the globe and 
possible bring a major challenges to human being for the survival followed struggling 
to keep the global economy on correct pace, if the spread of the virus is not effectively 
controlled. [5, 6]  
The causative agent of this devastating disease COVID-19 belongs to Beta 
coronavirus which shares 89.1% nucleotide similarity with acute respiratory syndrome 
coronavirus (SARS-CoV). [7] The key amino acid residues are conserved in many viral 
key drug targets, including those found in both SARS-CoV and COVID-19 pathogens. 
Consequently, many common viral targets are structurally similar to SARS-CoV and 
likely to be inhibited by the same compounds. The emergence of COVID-19 has 
severely compromised the arsenal of antiviral and antibiotic drugs. New compounds 
and targets are needed to meet the growing threat from Beta coronavirus. The 
possibility that COVID-19 and other viruses/bacteria can be perniciously engineered 
as biowarfare agents creates another demand for new treatment options. Drug 
discovery is a multistep process with a high attrition rate, substantial cost and slow 
pace of development of new molecules into the clinical candidate. On the other side, 
drug repurposing also called old drugs for new uses, is an attractive alternative 
approach for the new application of FDA approved or investigational drugs that are 
outside the scope of the original medical condition. [8] There is a plethora of literature 
evidence indicated the vital application of drug repurposing for various infectious 
diseases.[9-11] Given the current scenario of COVID-19 outbreak across the world 
and the complex nature of the disease repurposing of existing FDA approved drugs is 
the first line of the treatment. 
Given the pandemic nature of the disease, there is a hard-pressing need to uncover 
the possible treatment/s as early as possible. The researchers and physicians have 
been putting sincere efforts to understand this new virus, the pathophysiology of the 
disease to and the possible therapeutic effective agents and vaccines. Tremendous 
effects have been done to study the newly emerged virus and find potent drugs for 
clinical usage. A PubMed search with key work COVID-19 resulted in more than 900 
publications from November 01, 2019, to April 31, 2020. A glance at the title of these 
papers indicated that the majority are focused on manifestations and treatment 
options.  
It has been shown in the literature that the FDA approved antimalarial and autoimmune 
disease drug chloroquine (CQ) and hydroxychloroquine (HCQ), known to inhibit 
viral infection by raising endosomal pH necessary for the interaction of virus/cell 
fusion.[12, 13] [14] CQ and HCQ interferes ACE2 glycosylation or 
glycosyltransferases within human cells or inhibits sialic acid biosynthesis by inhibiting 
quinone reductase 2. The immunomodulatory property of chloroquine synergistically 
involved with the anti-viral property. The antiviral drug remdesivir (RDV) can inhibit 
the growth of COVID-19 and found to be efficacious in the clinic in combination.[13, 
15, 16] [17]The mechanism of action of RDV is under investigation, however, the high 
sequence similarity (>95%) between COVID-19 and SARS-CoV RNA-dependent RNA 
polymerase (RdRp) indicating the inhibition of RdRp. Similarly, the broad-spectrum 
virus-host cell fusion inhibitor marketed antiviral drug arbidol (ABD), prevents the 
entry of the virus entry into the host cell acting through ACE2 has entered into a clinical 
trial for the treatment of COVID-19. [18, 19] 
Inspired from the current pandemic situation and our experience in drug 
repurposing/drug design through computational and medicinal chemistry tools, we 
have carried docking studies with selected FDA approved drugs against COVID-19 
selected key protein targets. Given the complex nature of this rapidly and severely 
infecting lower respiratory system disease, our hypothesis is to identify FDA approved 
drug combinations targeting the different key viral proteins. The selection of the key 
proteins is based on the virus life cycle starting from attachment onto the human host, 
replication, viral latency (invasion from immunity), release and complex nature of the 
disease. The selection of four key targets:  PDB ID: 6LZG which is the structure of 
novel coronavirus spike receptor-binding domain complexed with its receptor ACE2; 
PDB ID: 6NUR a recently identified  SARS-Coronavirus NSP12 bound to NSP7 and 
NSP8 co-factors, PDB ID:  6W4H the crystal structure of NSP16-NSP10 Complex from 
SARS-CoV-2 of SARS-COV, and homology model of nonstructural protein 12 (nsp12) 
RNA-dependent RNA polymerase (RdRp) with RNA and without RNA. While we 
carried out the docking with the homology model of RdRP, the crystal structure of PDB 
ID: 6M71 SARS-Cov-2 RNA-dependent RNA polymerase in complex with cofactors 
was reported. So, we carried out the docking using this crystal structure as well. The 
online  COVID-19 Docking Server” (http://ncov.schanglab.org.cn) which contains the 
homology model of COVID-19 RdRp with RNA and without RNA was taken in the 
experiment. The non-structural proteins, nsp16-nsp10 and 3plPro play an important 
role in virus genome replication and evasion from innate immunity.  
 
Chloroquine(CQ)           Remdesivir(RDV)        Hydroxychloroquine(HCQ)   Arbidol(ABD) 
Figure 1:  Chemical structures of the selected FDA approved drugs for docking studies  
 
Experimental section 
Docking methodology:  Molecular docking studies are a method of providing 
valuable information on the rationale of designing ligands for a particularly active site 
of a well-known macromolecule. This is an economic and modern trend of drug 
discovery where technology base ligand-protein interaction reveals the pre-
synthesizing possibilities. The in-silico study of the four FDA drugs chloroquine (CQ), 
hydroxychloroquine (HCQ), remdesivir (RDV), and arbidol (ABD) (Figure 1) was 
performing blind docking both in online and offline modes.  
The offline docking was carried out using Autodock 4.2 program package 
(http://autodock.scripps.edu/).[20] The X-ray crystal structures of three different 
proteins were retrieved from the RCSB protein data bank (www.rscb.org). 
Macromolecule having PDB ID: 6LZG which is the structure of novel coronavirus spike 
receptor-binding domain complexed with its receptor ACE2; 6NUR a recently identified  
SARS-Coronavirus NSP12 bound to NSP7 and NSP8 co-factors, 6M71 SARS-Cov-2 
RNA-dependent RNA polymerase in complex with cofactors and 6W4H the crystal 
Structure of NSP16 - NSP10 Complex from SARS-CoV-2 of SARS-COV were 
selected based on the resolution and similarity with COVID-19. All the protein and 
ligand preparation were performed using MGL Tools 1.5.6 and Autodock Tool (ADT). 
The energy was minimized using Chem 3D program file. Standard precision with 
flexible ligand sampling was used and no specific grid was used at any stage of the 
experiment. The ADT was used to calculate the binding free energies and inhibition 
constant of the best-docked complex of the aforementioned proteins. Observation and 
visualization of the results were carried out using the latest version of Discovery Studio 
Visualizer (https://www.3dsbiovia.com/products/collaborative-science/biovia-
discovery-studio/visualization-download.php). Finally, the top binding modes are 
according to their energy calculation as the default parameter in AutoDoc.   
Further to expand the specificity, we performed online docking by using “The COVID-
19 Docking Server” (http://ncov.schanglab.org.cn) which contains the structure of the 
proteins involved in SARS-CoV virus life cycle based on the homologs of coronavirus. 
[21, 22] Ligands preparation and energy minimization were carried out using the Chem 
3D application and uploaded to the server in .mol2 format. Autodock Vina was used 
as a docking engine in the sever and prepared Nonstructural protein 12 (nsp12) RNA-
dependent RNA polymerase (RdRp) with RNA and without RNA was taken in the 
experiment. All the standard parameters were set as default except the 
exhaustiveness value is set to 12 to achieve higher accuracy. Visualization of the 
result was done by the latest version of Discovery Studio Visualizer and binding free 
energy was collected from the aforesaid web server.[23] 
Results and discussion:  
1. The binding mode analysis and predicated binding affinity calculations of 
chloroquine (CQ) against surface receptor and nonstructural proteins: The Auto 
dock software was used for molecular docking studies of chloroquine (CQ) against the 
novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 
(PDB ID 6LZG) revealed the interaction of CQ  with TRP349 ALA348 PRO346 
ASP350 as shown in Figure 2 A. The negative values of the binding free energy (-
6.67 kcal/mole) further indicated the stability of the complex (Table 1). The receptor 
pocket and top 10 conformers are shown in figure 2A. Similarly, the docking studies 
and binding mode analysis of CQ against SARS-Coronavirus NSP12 bound to NSP7 
and NSP8 co-factors (PDB ID 6NUR) showed the interactions with MET542 ALA558 
ARG624 SER682 SER681 ASP623 ASP452 ALA554 (figure 2B). The negative free 
energy calculation (-6.49 kcal/mole) as shown in table 1 is an indication of the 
interaction of CQ with nonstructural viral proteins. Our docking studies of CQ with 
NSP16- NSP10, however, our docking methodology did not work very well with this 
target resulted in the high positive values of binding energy (data are not shown here). 
We will further improve our next publications.   
 (i) (ii) (iii) (iv) 
A 
 
B 
 
C 
 
Figure 2: Conformational changes observed due to the binding of ligand Chloroquine 
with A. PDB ID: 6LZG, B. PDB ID: 6NUR, C. PDB ID: 6M71; left to right best pose, 
interaction 2D image of best pose, receptor pocket, and top10 conformers. 
  
  
  
Table 1: Binding affinity of chloroquine (C18H26ClN3) with the targets PDB ID: 6LZG, 
6NUR, and 6M71 
Rank PDB ID: 6LZG PDB ID: 6NUR PDB ID: 6M71 
Free 
Energy 
of 
Binding 
(kcal/mol 
Predicted
Inhibition 
Constant 
(μM) 
Interacting Amino 
Acids 
Free 
Energy of 
Binding 
(kcal/mol) 
Predicted 
Inhibition 
Constant 
(μM) 
Interacting Amino 
Acids 
Free 
Energy of 
Binding 
(kcal/mol) 
Predicted
Inhibition 
Constant 
(μM) 
Interacting 
Amino Acids 
1 -6.67 12.94 TRP349 ALA348 
PRO346 ASP350 
-6.49 17.52 MET542 ALA558 
ARG624 SER682 
SER681 ASP623 
ASP452 ALA554 
-3.44 3.03 ARG553 LYS621 
ARG624 TYR455 
ASP623 
2 -6.41 19.93 ARG393 ASP350 
ASP382 ALA348 
-5.81 55.13 ARG555 ARG624 
ASP623 
-3.27 4.03 LYS621 ASP623 
ARG553 
 
3 -6.35 22.3 ARG393 ASP382 
HIS401 GLU375 
ASP350 
-5.60 78.54 ASP623 LYS621 
ARG624 TYR455 
ARG553 
-3.25 4.15 ARG553 LYS621 
ASP623 ARG624 
TYR455 CYS622 
4 -6.20 28.47 HIS378 TRP349 
ALA348 ASP350 
-5.27 138.12 LYS545 ARG555 
ARG553 THR556 
ASP623 ASP452 
-3.24 4.21 ASP760 ASP623 
TYR455 LYS621 
ARG553  
5 -6.11 32.98 
 
 
HIS378 HIS345 
ALA348 Zn704 
-5.12 175.15 ASP623 SER682 
ALA558 VAL557 
ASP760 ARG624 
MET542 SER681 
-3.11 5.24 LYS621 ASP623 
ARG624 TYR455 
ASP760 
6 -6.06 36.02 HIS345 HIS378 
ALA348 ASP382 
-5.06 194.17 THR556 ASP623 
ARG555 LYS545 
ASP760 ARG553 
ASP452 
-3.01 6.17 ASN691 ASP760 
LYS621 ARG624 
TYR455 ARG553 
ASP623 
7 -6.04 37.31 ALA348 HIS401 
ARG393 ASP350 
ASP382 GLU375 
PRO346 
-5.01 212.38 
 
 
ALA558 THR680 
ARG624 ASP623 
THR556 
-2.73 9.95 TYR455 LYS621 
ARG553 ASP760 
8 -6.03 38.28 TYR385 HIS378 
ALA348 
-4.86 272.55 VAL557 ALA558 
THR556 TYR455 
TYR456 VAL667 
SER681 MET542 
ARG624 ASP452 
-2.71 10.26 TYR455 LYS621 
ARG624 ARG553 
ASP623  
9 -5.84 52.11 HIS378 ALA348 
PRO346 ASP382 
-4.86 272.16 LYS621 ASP623 
ASP760 TYR455 
ARG553 
-2.68 10.92 ARG553 ASP623 
LYS621 CYS622 
TYR619 
10 -5.68 68.86 HIS374 ASP382 
HIS378 HIS401 
ALA348 GLU375 
-4.76 324.02 ALA558 VAL667 
MET542 THR556 
ARG624 ASP623 
SER681 
-2.58 12.87 ALA558 ARG624 
MET542 ASP623 
TYR456 
 
2. The binding mode analysis and predicated binding affinity calculations of 
chloroquine against the homology model of COVID-19 RNA-dependent RNA 
polymerase (RdRP):  The viral nonstructural protein 12 (nsp12) or RNA-dependent 
RNA polymerase, RdRp) is essential for the replication and transcription of the viral 
genome. RdRp upon binding with the cofactors nsp7 and nsp8 catalyze the replication 
of RNA from an RNA template. The structure of viral RdRp of COVID-19 is not yet 
known, however, recently a web-based COVID-19 docking server has been launched 
which incorporates the homology model of RdRp built on PDB ID 6NUR, RdRp crystal 
structure of SARS-COV. Two structures of RdRp, one structure is constructed with 
RNA and others without RNA were reported for small molecules docking.  Therefore, 
this web-based server was utilized for docking studies of CQ. The docking studies of 
RdRp with RNA revealed the interaction of CQ with A Chain: ALA840 ARG858 
ARG555 ALA547 PHE441 ILE548 P Chain: G7 as shown in figure 3 A. The negative 
values of the binding free energy (-7.10 kcal/mole) further indicated the stability of the 
complex (Table 2). The receptor pocket and top 10 conformers are shown in figure 3 
A. Similarly, the docking studies of CQ on RdRp without RNA revealed the interaction 
of CQ with A Chain: ALA558 THR556 SER682 ASP452 ARG624 ASP623 as shown 
in figure 3 B. The negative values of the binding free energy (-6.20 kcal/mole) further 
indicated the stability of the complex (Table 2). The receptor pocket and top 10 
conformers are shown in figure 3 A.  
 (i) (ii) (iii) (iv) 
A 
 
B 
 
 
Figure 3: Best Conformation observed due to the binding of ligand chloroquine with 
Nonstructural protein 12 (nsp12) of SARS-CoV; A: nsp12 RdRp with RNA and B: 
nsp12 RdRp without RNA (Note: There are 2 neighboring binding pockets) 
 
 
 
 
 
 
 
 
 
 
  
  
Table 2: Binding affinity of chloroquine (C18H26ClN3) with the target nonstructural 
protein 12 (nsp12) of SARS-CoV 
 
3. The binding mode analysis and predicated binding affinity calculations of 
hydroxychloroquine (HCQ) against surface receptor and nonstructural proteins: 
The Auto dock software was used for molecular docking studies of hydroxychloroquine 
(HCQ) against the novel coronavirus spike receptor-binding domain complexed with 
its receptor ACE2 (PDB ID 6LZG) revealed the interaction of HCQ  with ASP382 
HIS378 HIS401 ASP350 TRP349 as shown in figure 4 A. The negative values of the 
binding free energy (-6.65 kcal/mole) further indicated the stability of the complex 
(Table 3). The receptor pocket and top 10 conformers are shown in figure 4A. 
Similarly, the docking studies and binding mode analysis of HCQ against SARS-
Coronavirus NSP12 bound to NSP7 and NSP8 co-factors (PDB ID 6NUR) showed the 
interactions with ASP452 VAL667 MET542 ALA558 VAL557 ARG624 SER682 
THR556 SER681 ASP623 (figure 4B). The negative free energy calculation (-6.75 
kcal/mole) as shown in table 3 is an indication of the interaction of HCQ with 
Cluster 
Rank 
NSP 12 RdRp with RNA NSP 12 RdRp without RNA 
Energy of 
binding 
Interacting Amino Acids Energy of 
binding 
Interacting Amino Acids 
1 -7.10 A Chain: ALA840 ARG858 
ARG555 ALA547 PHE441 
ILE548  
P Chain: G7 
-6.20 A Chain: ALA558 THR556 
SER682 ASP452 ARG624 
ASP623 
2 -6.70 A Chain: ARG858 ILE548 
ARG836 ALA547 PHE441 
P Chain: G6 G7 
-5.90 A Chain: SER682 THR556 
ASP452 ASP623 
3 -6.60 A Chain: ARG858 ILE548 
ALA547 PHE441 
P Chain: G6 G7 
-5.80 A Chain: ALA840 PHE441 
ARG836 ILE548 ALA547 
4 -6.60 A Chain: ALA547 LYS545  
P Chain: G6 G7 
-5.60 A Chain: LYS500 ALA685 
ARG569 
5 -6.30 A Chain: ARG836 ILE548 
ALA547 HIS439 
P Chain: G6 G7 
-5.60 A Chain: SER682 MET542 
ASP623 ARG624 
6 -6.30 A Chain: ALA547 PHE441 
ALA840 ILE548 ARG858 
P Chain: G6 G7 
-5.30 A Chain: ARG836 ALA840 
ILE548 
7 -6.20 A Chain: ILE548 ARG836 
ALA840 ARG858 
P Chain: G6 G7 
-5.20 A Chain: ALA547 ILE548 
ARG555 
8 -6.20 A Chain: ILE548 
P Chain: C4 C5 G6 
-5.20 A Chain: ARG624 ALA558 
ARG555 ASP623 THR556 
9 -6.00 A Chain: ALA840 PHE441 
VAL844 ARG858 ILE548 
P Chain: C5 G6 
-5.20 A Chain: ALA685 ALA688 
TYR689 
10 -5.90 A Chain: ARG555 HIS439 
ILE548 ALA840 ASP845 
P Chain: G7 
-5.10 A Chain: ASP845 ARG858 
nonstructural viral proteins. Our docking studies of HCQ with NSP16- NSP10, 
however, our docking methodology did not work very well with this target resulted in 
the high positive values of binding energy (data are not shown here). We will further 
improve our next publications.   
 (i) (ii) (iii) (iv) 
A 
 
B 
 
C 
 
 
Figure 4: Conformational changes observed due to the binding of ligand 
Hydroxychloroquine with A. PDB ID: 6lzg and B. PDB ID: 6nur, C. PDB ID: 6M71; left 
to right there is a pose of the best conformer, interaction 2D image of best pose, 
receptor pocket, and top10 conformers. 
Table 3: Binding affinity of Hydroxychloroquine (C18H26OClN3) with the target PDB 
ID: 6LZG, 6NUR, and 6M71 
 
Rank 
PDB ID: 6LZG PDB ID: 6NUR PDB ID: 6M71 
Free 
Energ
y of 
Bindi
ng 
(kcal/
mol) 
PredictedI
nhibition 
Constant 
(μM) 
Interacting 
Amino Acids 
Free 
Energ
y of 
Bindi
ng 
(kcal/
mol) 
Predicted
Inhibition 
Constant 
(μM) 
Interacting 
Amino Acids 
Free 
Energ
y of 
Bindi
ng 
(kcal/
mol) 
PredictedI
nhibition 
Constant 
(μM) 
Interacting 
Amino Acids 
1 -6.65 13.33 ASP382 HIS378 
HIS401 ASP350 
TRP349 
-6.75 11.21 ASP452 VAL667 
MET542 ALA558 
VAL557 ARG624 
SER682 THR556 
SER681 ASP623 
-3.62 2.22 ASP760 ASP623 
TYR456 MET542 
2 -5.99 40.96 ALA348 HIS401 
ARG514 
GLU402 
-6.46 18.32 ASP623 THR556 
ARG624 THR680 
SER681 SER682 
-2.88 7.81 ARG553 ASP623 
ASN691 
     
     
     
MET542 VAL667 
ALA558 
3 -5.70 66.75 ALA348 ASP350 
ASP382 HIS378 
HIS401 
-6.35 22.18 ASP623 ARG624 
MET542 ALA558 
VAL557 THR680 
-2.88 7.71 LYS621 ASP623 
SER682 THR556 
CYS622 TYR619 
4 -5.58 81.21 ALA348 ASP382 
HIS401 HIS374 
HIS378 
-6.22 27.52 TYR619 ASP623 
SER681 SER682 
ALA558 MET542 
ARG624 
-2.68 10.82 THR680 ASN691 
ASP623 ARG553 
TYR455 LYS621 
TYR619 CYS622 
5 -5.48 95.81 ALA348 ASP350 
ASP382 HIS401 
HIS374 Zn704 
GLU402 HIS378 
-6.17 30.12 ASP623 ALA554 
THR556 SER682 
SER681 ARG624 
MET542 ALA558 
-2.67 11.05 TYR619 LYS621 
ARG624 ALA558 
TYR456 MET542 
ASP623  
6 -5.14 171.38 ASP382 HIS401 
ALA348 ASP350 
-6.01 39.46 ASP452 ARG624 
ASP623 ALA558 
VAL557 MET542 
VAL667 SER681 
TYR456 SER682 
-2.42 16.97 ASP623 CYS622 
7 -5.05 198.05 GLU398 
ARG514 
GLU402 Zn704 
THR347 ALA348 
HIS378 HIS401 
-5.92 46.01 ASN691 THR680 
ASP760 ALA558 
MET542 VAL557 
ARG624 SER682 
ASP623 
-1.92 39.02 ASP623 TYR455  
8 -5.05 197.39 ALA348 ASP382 
HIS378 
-5.27 135.97 ARG553 ALA554 
ASP452 ASP623 
TYR456 SER681 
SER682 ARG624 
ALA558 MET542 
VAL667 
-1.26 118.92 SER682 ASP623 
ARG553 LYS621 
TYR455 
9 -4.83 286.00 GLU375 THR347 
ALA348 ASP382 
ARG393 
PHE390 ASP350 
-5.16 164.39 CYS622 ASP623 
ASP452 ARG624 
LYS621 TYR455 
ARG553 
-0.74 286.08 SER682 ARG553 
ARG624 ASP623 
LYS621 TYR455 
10 -4.47 526.55 ASP382 ALA348 
ASP350 TRP349 
HIS401 
-4.78 315.86 ALA554 ASP623 
ARG624 SER681 
SER682 MET542 
VAL667 ALA558 
-0.55 393.12 CYS622 ASP623 
ARG553 LYS621 
ARG624 
 
4. The binding mode analysis and predicated binding affinity calculations of 
hydroxychloroquine (HCQ) against the homology model of COVID-19 RNA-
dependent RNA polymerase (RdRP):  As mention in the binding mode of CQ with 
RdRp, Therefore, this web-based server was utilized for docking studies of HCQ. The 
docking studies of RdRp with RNA revealed the interaction of HCQ with A Chain:  
A Chain: ARG858 ILE548 ALA547 ARG836 
P Chain: G6 G7 as shown in figure 5 A. The negative values of the binding free 
energy (-7.20 kcal/mole) further indicated the stability of the complex (Table 2). The 
receptor pocket and top 10 conformers are shown in figure 5 A. Similarly, the docking 
studies of HCQ on RdRp without RNA revealed the interaction of HCQ with A Chain: 
TYR456 THR680 TYR455 ARG553 ASP623 as shown in figure 5 B. The negative 
values of the binding free energy (-6.00 kcal/mole) further indicated the stability of the 
complex (Table 2). The receptor pocket and top 10 conformers are shown in figure 5 
A.  
A Chain: ARG858 ILE548 ALA547 ARG836 
Figure 5: Best Conformation observed due to the binding of ligand hydroxychloroquine 
with Nonstructural protein 12 (nsp12) of SARS-CoV; A: nsp 12 RdRp with RNA (Note: 
There are 2 neighboring binding pockets) and B: nsp 12 RdRp without RNA (Note: 
There are 2 neighboring binding pockets) 
Note: Highlighted portion with yellow color indicates the amino acids interact with -
OH group present in HCQ. 
5. The binding mode analysis and predicated binding affinity calculations of 
remdesivir against surface receptor and nonstructural proteins: Molecular 
docking studies of remdesivir (RDV) against the novel coronavirus spike receptor-
binding domain complexed with its receptor ACE2 (PDB ID 6LZG) revealed the 
interaction of RDV with TYR385 ALA348 GLU398 ARG514 as shown in figure 6 A. 
The negative values of the binding free energy (-4.55 kcal/mole) further indicated the 
stability of the complex (Table 5). The receptor pocket and top 10 conformers are 
shown in figure 6 A.  Similarly, the docking studies and binding mode analysis of RDV 
against SARS-Coronavirus NSP12 bound to NSP7 and NSP8 co-factors (PDB ID 
6NUR) showed the interactions with ALA558 LYS676 ARG553 ASP623 ARG555 
SER682 TYR456 VAL667 VAL557 ARG624 (figure 6 B). The negative free energy 
calculation (-4.34 kcal/mole) as shown in table 3 is an indication of the interaction of 
RDV with nonstructural viral proteins. Our docking studies of RDV with NSP16- 
NSP10, however, our docking methodology did not work very well with this target  
resulted in the high positive values of binding energy (data are not shown here). We 
will further improve our next publications.   
A. 
    
B. 
 
   
Table 4: Binding affinity of Hydroxychloroquine (C18H26OClN3) with the target 
Nonstructural protein 12 (nsp12) of SARS-CoV  
 
A. 
    
 
 
 
 
 
Cluster 
Rank 
NSP 12 RdRp with RNA NSP 12 RdRp without RNA 
Energy of 
binding 
Interacting Amino Acids Energy of 
binding 
Interacting Amino Acids 
1 -7.20 A Chain: ARG858 ILE548 ALA547 
ARG836 
P Chain: G6 G7 
-6.00 A Chain: TYR456 THR680 TYR455 
ARG553 ASP623 
2 -7.00 A Chain: ARG836 ILE548 ALA547 
ARG858 PHE441 
P Chain: G6 
-5.90 A Chain: ASP623 ARG624 MET542 
ALA558 THR556 
3 -6.90 A Chain: ARG858 ALA840 ILE548 
P Chain: G6 G7 
-5.70 A Chain: ALA688 ALA685 LYS500 
ARG569 TYR689 
4 -6.70 A Chain: ALA840 ILE548 ARG836 
ARG555 
P Chain: G6 G7 
-5.70 A Chain: ARG555 LYS545 ARG858 
ILE548 ARG836 ALA547 
5 -6.60 A Chain: ARG836 ILE548 ARG858 
ALA547 PHE441 ALA840 ARG555 
P Chain: G7 
-5.60 A Chain: ASP452 THR556 ASP623 
SER682 ARG624 ALA558  
6 -6.50 A Chain: ILE548 ARG555 ASP845 
P Chain: C5 G7 G8 
-5.40 A Chain: ARG858 ILE548 ALA840 
ARG836 
7 -6.40 A Chain: ARG858 ILE548 ARG836 
ALA840 
P Chain: C5 G7 
-5.40 A Chain: ARG553 ILE548 ARG858 
PHE441 ALA840 ALA547 ARG555 
8 -6.40 A Chain: LYS545 THR556 ASP623 
ALA558 MET542 VAL667 ARG624  
P Chain: G8 
T Chain: G2 
-5.40 A Chain: ASP623 LYS621 TYR455 
ARG553 
9 -6.20 A Chain: THR556 SER682 ASP623  
P Chain: G8 
-5.40 A Chain: SER682 THR556 ASP623  
10 -6.20 P Chain: G6 G7 C5 -5.30 A Chain: SER682 THR556 ASP760 
ASP623 CYS622 
B. 
    
Figure 6: Conformational changes observed due to the binding of ligand remdesivir 
with A. PDB ID: 6LZG, B. PDB ID: 6NUR; left to right there are the best pose, 
interaction 2D image of best pose, receptor pocket, and top10 conformers. 
Table 5: Binding affinity of remdesivir (C27H35N6O8P) with the target protein PDB ID: 
6LZG, 6NUR 
Cluster 
Rank PDB ID: 6LZG PDB ID: 6NUR Free Energy of 
Binding 
(kcal/mol) 
Predicted 
Inhibition 
Constant 
(μM) 
Interacting Amino Acids Free Energy of 
Binding 
(kcal/mol) 
Predicted 
Inhibition 
Constant 
(μM) 
Interacting Amino Acids 
1 -4.55 461.75 μM TYR385 ALA348 
GLU398 ARG514 
-4.34 661.90 μM  ALA558 LYS676 ARG553 
ASP623 ARG555 SER682 
TYR456 VAL667 VAL557 
ARG624 
2 -4.32 679.89 μM HIS378 HIS401 ASN394 
ALA348 TRP349 ASP350 
-4.10 995.09 μM ASP452 ALA554 ARG624 
ARG555 THR556 MET542 
ALA558 SER682 TYR456 
LYS621 ARG553 ASP623 
3 -3.92 1.34 mM GLU402 ALA348 ASN394 
THR347 ASP382 HIS401 
-3.82 1.59 mM TYR455 ARG624 CYS622 
LYS621 ARG555 ASP623 
ASP452 ALA554 THR556 
ARG553 
4 -3.44 2.99 mM ARG514 HIS401 GLU402 
ASP382 ALA348 HIS345 
HIS378 GLU398 
-3.60 2.29 mM LYS621 TYR455 ARG553 
ARG624 THR556 ALA554 
ASP623 CYS622 
5 -3.09 5.42 mM Zn704 ALA348 ASP382 
HIS378 HIS401 ARG514 
-3.50 2.70 mM 
 
LYS545 ARG555 ASP623 
CYS622 ASP760 ARG624 
ARG553 SER682 VAL557 
6 -2.90 7.48 mM ARG393 PHE40 ASN394 
ALA348 ASP350 HIS401 
ASP382 Zn704 GLU402 
HIS378 
-2.95 6.92 mM ASP760 TYR455 CYS622 
ASP452 ASP623 THR556 
ARG624 ARG555 ARG553 
LYS621 
7 -2.81 8.75 mM HIS345 THR347 TRP349 
ALA348 HIS401 HIS378 
ASP382 
-1.08 160.23 mM LYS621 ARG624 THR556 
ASP452 ASP623 CYS622 
MET626 ARG553 
8 -2.78 9.15 mM TRP349 ASP350 ALA348 
HIS378 ASP382 ASN394 
GLU398 ASN397 PHE400 
-0.62 353.02 mM THR556 TYR455 ARG624 
THR680 ASP623 ALA554 
ARG553 LYS621 ARG555 
9 -2.45 15.87 mM ASP350 GLU375 PRO346 
HIS345 HIS378 GLU402 
HIS401 ALA348 
-0.44 472.51 mM ARG624 LYS621 ARG555 
THR556 TYR619 ARG553 
ASP452 ASP623 
10 -2.18 25.03 mM HIS345 HIS401 ARG393 
ALA348 PHE40 THR347 
ASP350 
4.23 NA TYR619 ASP623 ARG555 
ALA554 ASP452 ARG624 
THR556 ARG553 LYS621 
 
6. The binding mode analysis and predicated binding affinity calculations of 
remdesivir against the homology model of COVID-19 RNA-dependent RNA 
polymerase (RdRP):   As mentioned earlier the web-based was utilized for docking 
studies of RDV. The docking studies of RdRp with RNA revealed the interaction of 
RDV with A Chain: A Chain: PHE441 ALA547 ILE548 LYS545 ARG624 ASP452 
ASP623 ARG555 T Chain: G2 P Chain: G7 G8 as shown in figure 7 A. The negative 
values of the binding free energy (-9.40 kcal/mole) further indicated the stability of the 
complex (Table 6). The receptor pocket and top 10 conformers are shown in figure 7 
A. Similarly, the docking studies of RDV on RdRp without RNA revealed the interaction 
of RDV A Chain: TYR455 ARG553 ASP760 CYS622 ASP623 ARG624 THR680 
TYR456 ALA558 THR556 as shown in figure 7 A. The negative values of the binding 
free energy (-8.50 kcal/mole) further indicated the stability of the complex (Table 6). 
The receptor pocket and top 10 conformers are shown in figure 6 A. 
A. 
     
B. 
       
Figure 7: Best Conformation observed due to the binding of ligand remdesivir with 
Nonstructural protein 12 (nsp12) of SARS-CoV: A. nsp 12 RdRp with RNA and B. nsp 
12 RdRp without RNA 
Table 6: Binding affinity of remdesivir (C27H35N6O8P) with the target nonstructural 
protein 12 (nsp12) of SARS-CoV 
Cluster 
Rank 
NSP12 RdRp with RNA NSP 12 RdRp without RNA 
Energy of 
binding 
Interacting Amino Acids Energy of 
binding 
Interacting Amino Acids 
1 -9.40 A Chain: PHE441 ALA547 
ILE548 LYS545 ARG624 
ASP452 ASP623 ARG555 
T Chain: G2 
P Chain: G7 G8  
-8.50 A Chain: TYR455 ARG553 
ASP760 CYS622 ASP623 ARG624 
THR680 TYR456 ALA558 THR556 
2 -9.40 A Chain: LYS545 THR556 
ARG553 LYS621 TYR455 
ARG624 ASP623 ASP760 
T Chain: G2 
P Chain: G8 
-8.30 A Chain: TYR455 LYS621 
ARG553 THR556 ASP623 ARG624 
ALA558 TYR456 THR680 CYS622 
ASP760 
 7. The binding mode analysis and predicated binding affinity calculations of 
arbidol against surface receptor and nonstructural proteins: Molecular docking 
studies of arbidol (ABD) against the novel coronavirus spike receptor-binding domain 
complexed with its receptor ACE2 (PDB ID 6LZG) revealed the interaction of ABD with 
ASP350 TRP349 ALA348 HIS378 ASP382 HIS401  as shown in figure 8A. The 
negative values of the binding free energy (-7.49 kcal/mole) further indicated the 
stability of the complex (Table 7). The receptor pocket and top 10 conformers are 
shown in figure 8A.  Similarly, the docking studies and binding mode analysis of ABD 
against SARS-Coronavirus NSP12 bound to NSP7 and NSP8 co-factors (PDB ID 
6NUR) showed the interactions with ASP452 ARG553 THR556 ASP623 ARG624  
(Figure 8B). The negative free energy calculation (-6.31 kcal/mole) as shown in table 
5 is an indication of the interaction of ABD with nonstructural viral proteins. Our docking 
studies of ABD with NSP16- NSP10, however, our docking methodology did not work 
3 -9.30 A Chain: ARG555 ALA547 
PHE441 ILE548  
P Chain: C4 C5 G6 G7 G8 
-8.10 A Chain: ASP760 THR556 
ARG624 ASP452 TYR455 ARG553 
ASP623 
4 -9.10 A Chain: SER682 LYS545 
ARG555 ILE548 ASP760  
P Chain: G8 
-7.90 A Chain: THR680 ARG624 
TYR455 LYS621 ARG553 THR556 
SER682 ASP623 
5 -9.10 A Chain: VAL557 LYS545 
ARG555 ALA547 ILE548 
ARG858 ALA840 ASP845  
P Chain: C5 G6 G7 
-7.70 A Chain: ASP760 LYS621 CYS622 
THR680 TYR456 ALA558 
ARG624 ASP623 THR556 ARG553 
6 -9.00 A Chain: ALA840 ILE548 
LYS545 ARG555 ALA547 
PHE441 ASP452 ASP623  
P Chain: G8 
T Chain: G2 
-7.70 A Chain: LYS551 LYS621 
TYR455 THR680 ASP623 ARG553 
THR556 ARG555 SER682 
7 -9.00 A Chain: ILE548 PHE441 
ASP845 ASN497 LYS500 
ASP499 LYS545 ARG555 
T Chain: C3 G2 
P Chain: G7 
-7.70 A Chain: ASP618 TYR455 
LYS621 ARG553 ARG624 ASP623 
THR556 SER682 ASN691 THR680 
8 -9.00 A Chain: ARG555 LYS545 
ILE548 ALA840 ARG836 
ASP623 ARG624 ASP452  
T Chain: G2 
P Chain: G7 G8 
-7.60 A Chain: ASP452 TYR455 
LYS621 ARG553 ARG624 ASP623 
THR680 ASP760 THR556 
9 -9.00 A Chain: SER682 ASP623 
ARG624 ARG555 ALA840 
ALA547 PHE441 ILE548 
LYS545 
T Chain: G2 C3 
-7.50 A Chain: TYR455 ARG553 
LYS621 ASP760 CYS622 ASP623  
10 -8.90 A Chain: ASP452 ARG553 
TYR455 ASP623 CYS622 
ASP760 
P Chain: G8 
T Chain: G2 
-7.50 A Chain: TYR455 ASP452 
ARG553 ASP760 THR680 ALA688 
ASP623 CYS622 LYS621 
very well with this target resulted in the high positive values of binding energy (data 
are not shown here). We will further improve our next publications.   
A. 
    
B. 
    
Figure 8: Conformational changes observed due to the binding of ligand Arbidol with 
A. PDB ID: 6LZG, B. PDB ID: 6NUR; left to right best pose, receptor pocket, and top10 
conformers. 
Table 7: Binding affinity of arbidol (C22H25N2SO3Br) with the target protein PDB ID: 
6LZG, 6NUR. 
Cluster 
Rank 
PDB ID: 6LZG PDB ID: 6NUR 
Free 
Energy of 
Binding 
(kcal/mol) 
Predicted 
Inhibition 
Constant 
(μM) 
Interacting Amino 
Acids 
Free 
Energy of 
Binding 
(kcal/mol) 
Predicted 
Inhibition 
Constant 
(μM) 
Interacting Amino 
Acids 
1 -7.94 1.51 ASP350 TRP349 ALA348 
HIS378 ASP382 HIS401  
-6.31 23.79 μM ASP452 ARG553 THR556 
ASP623 ARG624  
2 -7.68 2.36 ASP382 HIS401 ASP350 
TRP349 ALA348 HIS378 
-5.69 67.69 μM TYR456 MET542 THR556 
ALA558 ASP623 ARG624 
VAL667 THR680  
3 -7.61 2.65 ASP350 TRP349 ALA348 
GLU375 ASP382 
-5.36 117.68 
μM 
ARG553 ARG555 THR556 
ASP623 ARG624 SER682 
ASP760 
4 -7.28 4.64 ALA348 ASP382 ASN394 
HIS401 GLU402  
-5.04 200.60 
μM 
TYR455 ARG553 ARG555 
THR556 ASP623 ARG624  
5 -7.09 6.37 ASP350 TRP349 ALA348 
HIS378 ASP382 HIS401 
-4.65 388.54 
μM 
ASP452 ARG553 ALA554 
THR556 CYS622 ASP623 
ARG624  
6 -7.01 7.22 HIS378 ASP382 ASN394 
HIS401 GLU402  
-4.52 489.35 
μM 
ASP452 LYS545 ARG553 
ALA554 ARG555 THR556 
ASP623 ARG624  
7 -6.72 11.96 ALA348 ASP350 HIS378 
ASP382 HIS401 ARG514  
-4.48 520.82 
μM 
ARG553 ARG555 THR556 
ASP623 ASP760  
 
 
8 -6.72 11.89 GLU375 HIS378 ASP382 
HIS401 
-3.93 1.32 mM ARG553 THR556 ALA558 
ASP623 ARG624 ASP760 
 
9 -6.39 20.68 ASP350 TRP349 ALA348 
HIS378 ASP382 HIS401  
-3.51 2.69 mM ASP452 ARG553 THR556 
ASP623  
10 -5.92 45.87 ALA348 HIS378 ASP382 
ASN394 HIS401 GLU402  
-3.48 2.82 mM TYR455 ASP623 ARG624 
ASP760 
 
8. The binding mode analysis and predicated binding affinity calculations of 
arbidol against the homology model of COVID-19 RNA-dependent RNA 
polymerase (RdRP):   As mentioned earlier the web-based was utilized for docking 
studies of ABD. The docking studies of RdRp with RNA revealed the interaction of 
ABD with TYR456 THR680 ASP452 ARG624 figure 9 A. The negative values of the 
binding free energy (-7.30 kcal/mole) further indicated the stability of the complex 
(Table 8). The receptor pocket and top 10 conformers are shown in figure 9 A. 
Similarly, the docking studies of ABD on RdRp without RNA revealed the interaction 
of ABD A Chain: TYR455 ARG553 ASP760 CYS622 ASP623 ARG624 THR680 
TYR456 ALA558 THR556 as shown in figure 9 A. The negative values of the binding 
free energy (-5.90 kcal/mole) further indicated the stability of the complex (Table 8). 
The receptor pocket and top 10 conformers are shown in figure 9 A. 
A. 
   
 
B. 
   
 
 
Figure 9: Best Conformation observed due to the binding of ligand arbidol with 
Nonstructural protein 12 (nsp12) of SARS-CoV; A: nsp 12 RdRp with RNA and B: nsp 
12 RdRp without RNA. 
Table 8: Binding affinity of arbidol (C22H25N2SO3Br) with the target nonstructural 
protein 12 (nsp12) of SARS-CoV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
Cluster 
Rank 
NSP 12 RdRp with RNA NSP 12 RdRp without RNA 
Energy of 
binding 
Interacting Amino Acids Energy 
of 
binding 
Interacting Amino Acids 
1 -7.30 A Chain: ASP452 THR556 
ASP623 ARG624  
P Chain: G8 
-5.90 A Chain: LYS545 THR556 
ASP623 ARG624 THR680 
SER682 ASP760 
2 -7.10 A Chain: PHE441 LYS545 
ALA547 ILE548 ARG555 
ASP845 ARG858 
P Chain: G6 G7 
-5.70 A Chain: ASP452 THR556 
ASP623 ARG624 ALA688 
3 -7.10 A Chain: ILE548 ARG555 
ASP845  
P Chain: G7 G8 
-5.70 A Chain: ASP452 ARG553 
THR566 ALA558 ASP623 
ARG624  
4 -7.00 A Chain: LYS545 ILE548 
ARG555  
P Chain: C5 G6 G7 
-5.30 A Chain: ASP452 ARG553 
THR556 TYR619 ASP623  
5 -7.00 A Chain: PHE441 LYS545 
ALA547 ILE548 ARG555 
VAL557 ASP845 ARG858  
P Chain: G6 G7 
-5.30 A Chain: ASP452 ALA554 
THR556 ASP623 ARG624 
ASP760 
6 -7.00 A Chain: LYS545 
ARG555  
P Chain: C5 G6 G7 
-5.30 A Chain: ASP452 ALA554 
THR556 ASP623 ARG624  
7 -6.80 A Chain: THR556 ASP623 
ARG624  
P Chain: G8 
-5.20 A Chain: THR556 ASP623 
ARG624 ALA688  
8 -6.80 A Chain: LYS545 
ARG555  
P Chain: G7 G8 
-5.20 A Chain: THR556 ASP618 
ASP623 ASP760 
9 -6.70 A Chain: ARG555 ASP623 
ASP760 
P Chain: G8 
-5.10 A Chain: LYS545 ARG553 
ARG555 THR556 ASP623  
10 -6.70 A Chain: LYS545   
P Chain: C5 G6 G7 G8 
T Chain: C4 
-5.10 A Chain: ARG553 CYS622 
ASP623 ASP760 
Here, we report the preliminary docking studies of the selected FDA approved drugs 
which have shown promising anti-COVID-19 activity. Literature evidences are 
indicating a single drug is probably not effective for the treatment of this disease. The 
viral polymerases and proteases are known to be the most suitable targets for the 
treatment of viral born disease. Therefore, we selected the targets to cover a range of 
targets starting from the entry point to the multiplication and release of the viruses. In 
our in-silico experiment based on mainly molecular docking approach, we investigated 
four different types of pharmacologically active and US-FDA approved drugs towards 
their potential application alone or in combination with drug repurposing. Our studies 
can give an insight into the possible the pocket(s) of ligand interaction, best conformer 
and its orientation and interactions with the respective targets. The molecules are 
arranged in decreasing order of their binding free energies, in respective tables. Based 
on their binding affinity, we found that these compounds may be potential inhibitors 
against SARS-CoV having promising interactions with the selected targets.  
Future direction and limitations of the study: The work presented here is a 
preliminary study based on the hypothesis to repurpose the FDA approved drugs to 
identify the combination therapy potentially targeting the various stages of the virus 
life cycle for the management of COVID-19. The study needs further investigation 
through the various computational tool and further detailed biological evaluation for 
the selection of possible combination therapy to potentially deal with the current 
pandemic situation.   
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